CD47 antibody inhibits tumor recurrence in a clinical relevant glioblastoma animal model by Huaiyang Zhu et al.
POSTER PRESENTATION Open Access
CD47 antibody inhibits tumor recurrence in a
clinical relevant glioblastoma animal model
Huaiyang Zhu1*, Ning Yang2, Lina Leiss1, Cecilie B Rygh1, Per Ø Enger1, Rolf Bjerkvig1, Jian Wang1
From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
National Harbor, MD, USA. 4-8 November 2015
Glioblastoma multiform (GMB), as a major unsolved clini-
cal challenge, remains among the most aggressive malig-
nan cies in human brain with poor prognosis. Although
radiotherapy and chemotherapy that were given to
patients after s urgery may improve overall survival, the
treatment outcomes in general are poor. Thus, new thera-
peutic strategy for GBM is urgently needed. CD47,
a tumor cell surface marker, plays as “don’t eat me signal”
through binding its recept or SIRPa on macrophages and
the antibody against CD47, which blocks interactions
of CD47 with SIRPa, has been shown to lead to tumor
destruction1. Furthermore, CD47 is a prognostic marker
as its expression predisposes cancer patients to a poorer
survival outcome. This has significant clinical implications
since approximately more than 80% of patients with the
most GBMs, overexpress CD47. The purpose of the cur-
rent study is to evaluate the feasibility of tar geting CD47
therapeutically as well as to explore its mechanism in a
highly clinical relevant GBM nude rat model. In t he
study, we have developed a novel xenograft surgical resec-
tion and tumor recurrence GBM model in parallel with t
he patient settings in clinic. The model accounted for the
therapeutic benefit of surgical resection and demonstrated
t hat recurrent tumors higher proliferation and more
dilated vessels in comparison with the primary tumors. It
also has been shown that the tumor resection recruited
more macrophages to the surgical site and by using the
anti-CD47 antibody significantly prolonged animal survi-
val. Moreover, angiogenesis array showed the angiogenic
factors were down-regulated in the group of the animals
treated with CD-47 antibody and cytokines array showed
the cytokines that are related to immune responses and
antitumor activities were up-regulated by the CD47
antibody. These results suggest that the presence of
macrophages postoperatively was needed to mediate the
anti-tumor effects of the anti-CD47 antibody and CD47 is
the potential therapeutic target for recurrent GBM.
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